JP2018537514A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537514A5 JP2018537514A5 JP2018531667A JP2018531667A JP2018537514A5 JP 2018537514 A5 JP2018537514 A5 JP 2018537514A5 JP 2018531667 A JP2018531667 A JP 2018531667A JP 2018531667 A JP2018531667 A JP 2018531667A JP 2018537514 A5 JP2018537514 A5 JP 2018537514A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- bladder
- use according
- hal
- light
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 24
- 206010005003 Bladder cancer Diseases 0.000 claims 5
- 239000007788 liquid Substances 0.000 claims 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 238000009098 adjuvant therapy Methods 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 238000009799 cystectomy Methods 0.000 claims 2
- -1 hexyl 5-ALA ester Chemical class 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- XMEKHKCRNHDFOW-UHFFFAOYSA-N O.O.[Na].[Na] Chemical compound O.O.[Na].[Na] XMEKHKCRNHDFOW-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims 1
- 235000019796 monopotassium phosphate Nutrition 0.000 claims 1
- 238000009099 neoadjuvant therapy Methods 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 239000008055 phosphate buffer solution Substances 0.000 claims 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1522309.2 | 2015-12-17 | ||
| GBGB1522309.2A GB201522309D0 (en) | 2015-12-17 | 2015-12-17 | Use |
| PCT/EP2016/081803 WO2017103283A1 (en) | 2015-12-17 | 2016-12-19 | Neoadjuvant therapy for bladder cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537514A JP2018537514A (ja) | 2018-12-20 |
| JP2018537514A5 true JP2018537514A5 (enExample) | 2020-02-06 |
| JP6926086B2 JP6926086B2 (ja) | 2021-08-25 |
Family
ID=55311159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531667A Active JP6926086B2 (ja) | 2015-12-17 | 2016-12-19 | 膀胱癌のための術前補助療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10556010B2 (enExample) |
| EP (1) | EP3389717B9 (enExample) |
| JP (1) | JP6926086B2 (enExample) |
| KR (1) | KR102787188B1 (enExample) |
| CN (2) | CN119345359A (enExample) |
| AU (1) | AU2016372573B2 (enExample) |
| BR (1) | BR112018012009B1 (enExample) |
| CA (1) | CA3008551A1 (enExample) |
| DK (1) | DK3389717T3 (enExample) |
| ES (1) | ES3015668T3 (enExample) |
| FI (1) | FI3389717T3 (enExample) |
| GB (1) | GB201522309D0 (enExample) |
| PL (1) | PL3389717T3 (enExample) |
| WO (1) | WO2017103283A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201522309D0 (en) * | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
| GB201522311D0 (en) * | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
| PH12020550124B1 (en) * | 2017-12-01 | 2024-05-24 | Nat Ct Child Health & Dev | Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor |
| KR102441358B1 (ko) | 2020-09-14 | 2022-09-06 | 주식회사 아파트엔 | 아파트의 지수화를 통한 아파트 투자 가치 평가 시스템 |
| AU2024231397A1 (en) | 2023-03-07 | 2025-09-25 | Photocure Asa | Therapy for bladder cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ291132B6 (cs) | 1995-03-10 | 2002-12-11 | Photocure Asa | Estery kyselin 5-aminolevulových a farmaceutický prostředek s jejich obsahem |
| US7530461B2 (en) * | 1995-03-10 | 2009-05-12 | Photocure Asa | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
| GB0018528D0 (en) * | 2000-07-27 | 2000-09-13 | Photocure Asa | Compounds |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| GB0406917D0 (en) | 2004-03-26 | 2004-04-28 | Photocure Asa | Compounds |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| CN102458388B (zh) | 2009-06-11 | 2016-09-28 | 光治疗Asa公司 | 半固体组合物及药物制品 |
| AR087405A1 (es) | 2011-08-01 | 2014-03-19 | Genentech Inc | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek |
| EP2785375B1 (en) | 2011-11-28 | 2020-07-22 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
| EP2855528B1 (en) | 2012-05-31 | 2019-06-19 | Genentech, Inc. | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
| US8927761B2 (en) | 2012-06-28 | 2015-01-06 | Photocure Asa | Form of hexyl-5-aminolevulinate hydrochloride and methods of using the same |
| WO2014020164A1 (en) * | 2012-08-03 | 2014-02-06 | Photocure Asa | Compounds |
| GB201522309D0 (en) * | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
| CN109010850B (zh) * | 2018-08-01 | 2021-10-22 | 上海师范大学 | 一种负载姜黄素的葡聚糖修饰的钆掺杂的空心介孔二氧化硅纳米材料的制备方法及应用 |
-
2015
- 2015-12-17 GB GBGB1522309.2A patent/GB201522309D0/en not_active Ceased
-
2016
- 2016-12-19 KR KR1020187020006A patent/KR102787188B1/ko active Active
- 2016-12-19 FI FIEP16819894.3T patent/FI3389717T3/fi active
- 2016-12-19 WO PCT/EP2016/081803 patent/WO2017103283A1/en not_active Ceased
- 2016-12-19 CA CA3008551A patent/CA3008551A1/en active Pending
- 2016-12-19 PL PL16819894.3T patent/PL3389717T3/pl unknown
- 2016-12-19 US US16/063,185 patent/US10556010B2/en active Active
- 2016-12-19 CN CN202411498667.9A patent/CN119345359A/zh active Pending
- 2016-12-19 ES ES16819894T patent/ES3015668T3/es active Active
- 2016-12-19 CN CN201680079674.2A patent/CN108601836A/zh active Pending
- 2016-12-19 JP JP2018531667A patent/JP6926086B2/ja active Active
- 2016-12-19 AU AU2016372573A patent/AU2016372573B2/en active Active
- 2016-12-19 DK DK16819894.3T patent/DK3389717T3/da active
- 2016-12-19 BR BR112018012009-0A patent/BR112018012009B1/pt active IP Right Grant
- 2016-12-19 EP EP16819894.3A patent/EP3389717B9/en active Active
-
2020
- 2020-01-21 US US16/748,332 patent/US11311620B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537514A5 (enExample) | ||
| JP2014094963A5 (enExample) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| NZ609719A (en) | Pharmaceutical composition | |
| AR074826A1 (es) | Regimen de dosificacion para un agonista de los receptores de s1p | |
| MX360684B (es) | Silicato de zirconio microporoso para el tratamiento de la hipercalemia. | |
| RU2012118974A (ru) | Комбинации ингибитора pi3k и ингибитора мек | |
| JP2020507589A5 (enExample) | ||
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| JP2016501066A5 (enExample) | ||
| JP2017513928A5 (enExample) | ||
| JP2017513927A5 (enExample) | ||
| FI3389717T3 (fi) | Neoadjuvanttihoito virtsarakon syöpää varten | |
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| JP2017509623A5 (enExample) | ||
| JP2018538308A5 (enExample) | ||
| JP2019501161A5 (enExample) | ||
| RU2013131241A (ru) | Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака | |
| RU2008108516A (ru) | 3,11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИН ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНОГО ЗАБОЛЕВАНИЯ ИЛИ ВОСПАЛЕНИЯ | |
| RU2007118691A (ru) | Применение 4-трифторметилфениламида (z)-2-циано-3-гидрокси-бут-2-еновой кислоты для лечения воспалительных заболеваний кишечника | |
| RU2018123834A (ru) | Способ фотодинамической терапии (фдт) для рака мочевого пузыря | |
| RU2015139515A (ru) | Комбинированное лечение | |
| JP2015521598A5 (enExample) | ||
| MX2022009081A (es) | Absorcion celular. | |
| Ogbadoyi et al. | Anemia in experimental African trypanosomiasis |